Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma

 Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma

Merck & Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma

Shots:

  • The third BT designation is based on P-Ib KEYNOTE-524 study assessing Keytruda (200mg, IV, q3w) + Lenvima (12/8 mg/day) in patients with unresectable HCC not amenable to locoregional treatment
  • The dual regimen has received its first two BT designation for advanced and metastatic renal carcinoma and non-microsatellite instability-high/proficient mismatch repair endometrial carcinoma in Jan’18 and Jul’18, respectively
  • Keytruda is an anti-PD-1 therapy blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activate T lymphocytes affecting both tumor & healthy cells. Eisai’s Lenvima is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR 1, 2 & 3

Click here to read full press release/ article | Ref: Merck | Image: Bucks County Courier Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post